Abstract
Antidiabetic medications that improve glycemic control as well as cardiovascular outcomes will be the mainstay of treatment for type 2 diabetes moving forward. This article reviews the beneficial effects of the thiazolidinedione pio-glitazone of ameliorating hyperglycemia and improving cardiovascular risk factors. While the newer sodium–glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist drug classes have confirmed cardiovascular benefits, pioglitazone also has been shown to reduce major adverse cardiovascular events, in both people with type 2 diabetes and nondiabetic subjects with insulin resistance. Adverse effects associated with pioglitazone can be miti-gated by its use at a lower dose and in combination with antidiabetic agents from other drug classes.
Original language | English (US) |
---|---|
Pages (from-to) | 243-247 |
Number of pages | 5 |
Journal | Diabetes Spectrum |
Volume | 34 |
Issue number | 3 |
DOIs | |
State | Published - Aug 2021 |
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism